Shandong Sinobioway Biomedicine Co.,Ltd. Class A

As of June 30, 2026, Shandong Sinobioway Biomedicine Co.,Ltd. Class A carries a market capitalization of 2.09B, placing it among publicly traded companies globally. Its enterprise value stands at 2.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shandong Sinobioway Biomedicine Co.,Ltd. Class A has 659.74M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 5.87, and the price-to-book ratio stands at 1.18.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.00B versus a market cap of 2.09B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shandong Sinobioway Biomedicine Co.,Ltd. Class A maintains a current ratio of 4.64, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 601,251.25 in revenue per employee across its workforce of 495.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.91 indicates how many times Shandong Sinobioway Biomedicine Co.,Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shandong Sinobioway Biomedicine Co.,Ltd. Class A recorded an income tax benefit of -7.11M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 23, 2026, Shandong Sinobioway Biomedicine Co.,Ltd. Class A's stock has declined approximately 36.57% over the past 52 weeks. The 50-day moving average sits at 5.03, while the 200-day moving average is 5.76.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, Shandong Sinobioway Biomedicine Co.,Ltd. Class A holds 242.84M in cash and equivalents against 58.15M in total debt, resulting in a net debt position of -187.99M. Total book value stands at 1.77B, with working capital of 493.38M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shandong Sinobioway Biomedicine Co.,Ltd. Class A posted a gross margin of 36.13, reflecting its pricing power and cost economics.

Shandong Sinobioway Biomedicine Co.,Ltd. Class A's most recent stock split took place on July 13, 2015 with a 1:2 split ratio.